N. Thalange Et Al. , "Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years," DIABETES THERAPY , vol.7, no.4, pp.713-724, 2016
Thalange, N. Et Al. 2016. Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years. DIABETES THERAPY , vol.7, no.4 , 713-724.
Thalange, N., BEREKET, A., Jensen, L. B., Hiort, L. C., & Peterkova, V., (2016). Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years. DIABETES THERAPY , vol.7, no.4, 713-724.
Thalange, Nandu Et Al. "Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years," DIABETES THERAPY , vol.7, no.4, 713-724, 2016
Thalange, Nandu Et Al. "Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years." DIABETES THERAPY , vol.7, no.4, pp.713-724, 2016
Thalange, N. Et Al. (2016) . "Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years." DIABETES THERAPY , vol.7, no.4, pp.713-724.
@article{article, author={Nandu Thalange Et Al. }, title={Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years}, journal={DIABETES THERAPY}, year=2016, pages={713-724} }